This site uses cookies to give you a better browsing experience.

You can find out more about the cookies we use here.

X Close

Are you a healthcare professional?

To access this website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.

Please click on the appropriate button below to confirm that you are a healthcare professional.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
  • Prescribing Information
  • AE Reporting
  • Important Safety Information
  • Continue to tevapharm.com
Menu
Menu

AJOVY® is indicated for prophylaxis of migraine in adults who have at least four migraine days per month1

Menu
  • Moa
  • Trials
  • Efficacy
  • Safety profile
  • Flexibility
  • Administration
  • Resources

YOU ARE NOW LEAVING THIS WEB SITE

This Web site may contain links or references to other Web sites maintained by third parties over whom Teva, Inc. ("Teva") has no control. Links are provided as a convenient resource to our visitors. We carefully choose Web sites which we believe are useful based on our high standards. However, Web sites can change. Teva cannot guarantee the standards of every Web site link or be responsible for the content of non-Teva Web sites. Inclusion of any third-party link does not imply an endorsement or recommendation by Teva.

Similarly, this Web site may be accessed from third-party links over which Teva has no control. Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such Web sites and shall have no liability for any damages or injuries of any kind arising from such content or information.

Continue Stay Here

Site map

    Home

    MOA

    EFFICACY

    Safety profile

    Flexibility

    Administration

    Clinical Trials

    Resources

    Privacy Notice

    Legal Notice

    Prescribing Information

Important Safety Information

Adverse events should be reported. Reporting forms and information can be found at www.gov.uk/yellowcard.
     Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com

Contraindications: AJOVY® is contraindicated in patients with hypersensitivity to fremanezumab or to any of the excipients1

Hypersensitivity Reactions: Hypersensitivity reactions were reported with fremanezumab in less than 1% of patients in clinical trials. If a hypersensitivity reaction occurs, discontinuation of fremanezumab administration should be considered and appropariate therapy should be initiated.1 During post-marketing surveillance there have been rare reports of anaphylaxis within the European Union (these are currently under review by Medicines and Healthcare products Regulatory Agency.

Adverse Events: The most common adverse reactions were injection site reactions1

Indication

AJOVY® is indicated for prophylaxis of migraine in adults who have at least four migraine days per month1

Please see the Prescribing Information for AJOVY®

Back to top
Legal Notice
Privacy Notice
Prescribing Information
Site Map
PAAB Logo

AJO-GB-00188 | Date of Preparation: January 2022 | Teva UK Limited, Ridings Point, Whistler Drive, Castleford, WF10 5HX